Masakazu Takeuchi

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura et al. · The Lancet Diabetes & Endocrinology · 2022 · 191 citations

Diabetes Management, Diabetes, Pharmacology +7

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in <scp>J</scp> apanese patients with type 2 diabetes: a randomized, open‐label, phase <scp>III</scp> , non‐inferiority study

Eiichi Araki, Nobuya Inagaki, Yukio Tanizawa et al. · Diabetes Obesity and Metabolism · 2015 · 78 citations · Full text

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

Yasuo Terauchi, Yoichi Satoi, Masakazu Takeuchi et al. · Endocrine Journal · 2014 · 50 citations · Full text

Diabetes Management, Diabetes, Pharmacology +8

Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires

Hitoshi Ishii, James H. Anderson, Ayuko Yamamura et al. · Diabetes Research and Clinical Practice · 2008 · 50 citations

Obesity, Quality Of Life, Metabolic Syndrome +12

Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes ( <scp>SURPASS</scp> J‐mono substudy)

Daisuke Yabe, Dan Kawamori, Yusuke Seino et al. · Diabetes Obesity and Metabolism · 2022 · 37 citations · Full text